In order to provide a broader platform for cancer treatment, the study communities further identify small molecule inhibitors targeting either histone methyltransferases or demethylases for the therapy of CRC, therefore most of the histone modifying enzymes serve as a drug target has been widely reported [76]. This evidence concerns the gene MBD2 and cancer.